Form 4: CRISPR Therapeutics CEO Sells Shares
Insider Transaction (Form 4)
Samarth Kulkarni, Chief Executive Officer and a Director of CRISPR Therapeutics AG, sold 4,098 shares of common stock on October 13, 2026 for $49.26 per share.
Summary
- Option exercise/conversion: acquired 8,333 Common Shares on October 13, 2026; holds 263,834 after (Direct).
- Open-market sale: disposed of 4,098 Common Shares at $49.26 ($201,867) on October 14, 2026; holds 259,736 after (Direct).
- Option exercise/conversion: disposed of 8,333 Restricted Stock Units on October 13, 2026 (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative signal: an insider sold $201,867 of stock on the open market.
Insider Transactions
Samarth Kulkarni — Director, Officer (Chief Executive Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-10-13 | Option exercise/conversion | Common Shares | 8,333 | — | — | 263,834 |
| 2026-10-14 | Open-market sale | Common Shares | 4,098 | $49 | $201.9K | 259,736 |
| 2026-10-13 | Option exercise/conversion | Restricted Stock Units | 8,333 | — | — | 0 |
Key Dates
| Date | Description |
|---|---|
| 2026-10-13 | Option exercise/conversion (8,333 shares) |
| 2026-10-14 | Open-market sale (4,098 shares) |
| 2026-10-13 | Option exercise/conversion (8,333 shares) |
Keywords
insider transaction, Form 4, CRSP, CRISPR Therapeutics AG, bearish, Samarth Kulkarni
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.